We thank Rashid and colleagues \[[@CR1]\] and Honoré and colleagues \[[@CR2]\] for their comments regarding our article on risk factors for acute kidney injury in patients receiving colistin or other nephrotoxic antimicrobials \[[@CR3]\].

It is correct that we did not specifically report urine output in the text, but it was obviously included in the RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria reported in Table two \[[@CR3]\].

We agree that the colistin methanesulfonate pharmacokinetics have been better studied recently, and it has become clear that high doses are required for treating multidrug-resistant Gram-negative bacilli infection, including the loading dose (which has changed from 4 to 9 million IU) and the dose interval (which has changed from three to two times a day) \[[@CR4]\]. We agree with the authors' concerns about the adequacy of colistin dosages adopted in our cohort (130,000 IU/kg of ideal body weight, modified according to renal function), but these doses were commonly adopted, especially in patients with renal impairment \[[@CR5]\]. Indeed, the development of new high-performance liquid chromatography assays that allow clinicians to measure the concentrations of colistimethate and colistin separately has shown that colistin clearance is due mainly to non-renal mechanisms that are still unclear. It is of great interest to note, as reported recently by Honoré and colleagues \[[@CR6]\], that patients with multidrug-resistant infections can receive even higher doses of colistin during continuous renal replacement therapy, as colistin methanesulfonate is continuously filtered and absorbed by dialysis membrane \[[@CR7]\]. Hence, even higher doses may be needed in patients receiving continuous renal replacement therapy than in patients with normal renal function. The growing evidence in favor of a higher dosage of colistin requires further clinical studies.

See related letters by Rashid *et al*., <http://ccforum.com/content/18/1/401>, and Honoré *et al*., <http://ccforum.com/content/18/1/412>, and related research by Rocco *et al*. <http://ccforum.com/content/17/4/R174>

**Competing interests**

The authors declare that they have no competing interests.
